Italia markets closed

FibroGen, Inc. (0IL8.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
14,74-0,03 (-0,20%)
Alla chiusura: 04:46PM GMT
Schermo intero
Chiusura precedente14,77
Aperto14,47
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno14,45 - 14,74
Intervallo di 52 settimane14,45 - 14,74
Volume350
Media VolumeN/D
Capitalizzazione10,419M
Beta (5 anni mensile)0,84
Rapporto PE (ttm)N/D
EPS (ttm)-3,04
Prossima data utili27 feb 2023 - 03 mar 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference

    SAN FRANCISCO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Bank of America 2022 Biotech SMID Cap Virtual Conference on December 8, at 1:05 PM Eastern Time. A live audio webcast of the event will be available on the “Events & Presentations” section of the FibroGen Investors webpage at www.fibrogen.com. The replay will be available for approximately 30 days. About FibroGen

  • GlobeNewswire

    FibroGen Reports Third Quarter 2022 Financial Results

    Continued advancement of pamrevlumab clinical trials – topline data from five pivotal Phase 3 trials beginning in 1H 2023 through mid-2024Completed enrollment of MATTERHORN Phase 3 study of roxadustat in patients with anemia of myelodysplastic syndromes with topline data expected 1H 2023Strong roxadustat volume growth in China of over 80% vs 3Q 2021Announced non-dilutive royalty monetization transaction with NovaQuest for $50 million of capital secured by 22.5% of roxadustat royalty revenue in t

  • GlobeNewswire

    FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management

    Strengthens balance sheet with strategic non-dilutive capital to support strategic prioritiesSupported by global launches of EVRENZO™ in the territories partnered with Astellas Pharma Inc.FibroGen will receive $50 million in total cash upfront SAN FRANCISCO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced a royalty monetization financing with NovaQuest Capital Management (NovaQuest) that will result in proceeds to FibroGen in the amount of $50 million, bringing no